New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For GE;DELL;GSK;AZN;BEN;AAPL From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
<< 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | all recent news | >>
July 28, 2015
09:42 EDTAAPLActive equity options trading on open
Active equity options trading on open: AAPL BIDU FB NFLX F T FCX TWTR
07:20 EDTAZNBrookings Institute to hold a public meeting
Subscribe for More Information
July 27, 2015
19:54 EDTAAPLApple Music reaches 10M subscribers in four weeks, HITS says
Subscribe for More Information
17:31 EDTGSKRadius Health hires Dr. Lorraine Fitzpatrick as Chief Medical Officer
Radius Health (RDUS) announced that it has hired Dr. Lorraine A. Fitzpatrick as Chief Medical Officer of the Company. Dr. Fitzpatrick was previously Medicine Development Leader of an international clinical development team for Denosumab at GlaxoSmithKline (GSK), responsible for clinical development, regulatory, manufacturing, commercial, operations, epidemiology, and global health outcomes. Previously, Dr. Fitzpatrick led the clinical development of novel agents to treat musculoskeletal diseases and women's health at GlaxoSmithKline. Before joining GlaxoSmithKline, Dr. Fitzpatrick was Executive Director at Amgen, Inc. where she worked in the fields of osteoporosis and oncology.
16:00 EDTAAPLOptions Update; July 27, 2015
Subscribe for More Information
13:16 EDTAAPLADT rises after Citi downplays 'smart home' concerns
Shares of ADT (ADT) are heading higher in afternoon trading following an upgrade from Citi, within which the research firm said traditional home security firms have plenty of traction as self-installed, self-monitored security solutions from the likes of Apple (AAPL) and Google's (GOOG) Nest are slow to be adopted by homeowners. WHAT'S NEW: Citi's Jason Bazinet issued a research note on the home security sector, upgrading ADT to Buy from Neutral while slightly lowering his price target to $39 from $40. Bazinet notes that the sector is expanding into "smart home" technology powered by companies like Apple and Google's Nest. Despite this, the analyst contends that consumer data shows continued preference for the traditional approach in the form of professionally installed and professionally monitored services from ADT, Monitronics, Vivint, AT&T (T) and Comcast (CMCSA, CMCSK). WHAT'S NOTABLE: Though tech firms and venture capitalists seem drawn towards the concept of self-installed, self-monitored "smart homes," consumers appear to be sticking with the professionals, says Citi. Security systems using Apple HomeKit and Google's Nest products are seeing "limited" adoption, and firms like ADT -- equipped with call centers and installation specialists -- appear ready to "hold their own," with recent weakness in ADT shares called an "opportunity" by Bazinet. The analyst conceded that professional security providers will see their market share drop to 15% from a current 20%, but Bazinet set a 2035 date for that shift, leaving plenty of near-term opportunity for traditional players. PRICE ACTION: After a 25% drop since mid-April, shares of ADT are up about 1.4% to trade near $32 this afternoon.
12:46 EDTGEAlstom to accept EUR300M hit to assist GE deal completion
Subscribe for More Information
10:13 EDTBENHigh option volume stocks
Subscribe for More Information
10:07 EDTAAPLApple falls, levels to watch
Subscribe for More Information
09:36 EDTAAPLActive equity options trading on open
Active equity options trading on open: AAPL NFLX INTC MU VZ BIDU AMBA
08:30 EDTAAPLNew Apple ipad mini rumored to be 'miniature iPad Air 2,' AppleInsider says
Subscribe for More Information
08:03 EDTGSKNephroGenex names Jaikrishna Patel as Chief Medical Officer
NephroGenex (NRX) announced the appointment of Dr. Jaikrishna Patel to the position of Chief Medical Officer. Dr. Patel will help guide the company’s Phase 3 PIONEER program with oral Pyridorin for the treatment of diabetic nephropathy, and the development of an intravenous formulation of Pyridorin for acute kidney injury. Patel has held numerous positions of increasing responsibility at GlaxoSmithKline (GSK) and its predecessor companies, most recently serving as Vice President of Cardiovascular and Cardiovascular Metabolism, Global Regulatory Affairs.
07:49 EDTAAPLApple said to talk with BMW about electric car project, MacRumors reports
Subscribe for More Information
06:38 EDTGEGE intends to be 'sizable' player in energy storage market, Reuters reports
Subscribe for More Information
06:36 EDTAAPLNike to pay $2.4M to FuelBand customers, AppleInsider reports
Under terms agreed upon in June, Nike (NKE) will pay $2.4M to customers who purchased a FuelBand product anytime between January 19, 2012 and June 17, 2015 to settle a class action suit leveled against itself and Apple (AAPL) in 2013, AppleInsider reports. Apple was named as a defendant in the suit, but holds no responsibility or liability for attorneys' fees or costs, the report says. The plaintiffs alleged that the Fuelband was unable to accurately track calorie burn, steps, and overall activity, the report says. Reference Link
06:30 EDTAAPLSky prepares to unveil set-top box, Telegraph reports
Sky is finishing up an advanced set-top box called SkyQ, a device it hopes can help its pay-TV business compete against BT (BT), the Telegraph reports. The new hardware is set to be unveiled in the next few weeks and will offer satellite households an "Apple (AAPL) and Netflix (NFLX) style" experience, the report says, citing industry insiders. Reference Link
06:05 EDTAAPLBest Buy to begin selling Apple Watch in August, WSJ reports
Subscribe for More Information
05:25 EDTAZNGenzyme acquires Caprelsa from AstraZeneca for $300M
Genzyme, a Sanofi (SNY) company, announced that it has entered into a definitive agreement with AstraZeneca (AZN) to acquire Caprelsa, a rare disease therapy, indicated for the treatment of symptomatic or progressive medullary thyroid carcinoma in patients with unresectable locally advanced or metastatic disease. Caprelsa is an oral kinase inhibitor treatment and is currently available in 28 countries. Caprelsa is in Phase III development for differentiated thyroid carcinoma, with the study expected to finish in the second half of 2015. Under the terms of the agreement, Genzyme will pay AstraZeneca up to $300M, including an upfront payment of $165M to acquire the global rights to sell and further develop Caprelsa, and further development and sales milestone payments of up to $135M. The transaction does not include the transfer of any AstraZeneca employees or facilities.
July 24, 2015
16:30 EDTAAPLStocks end week lower as Apple headlines busy week of earnings
Subscribe for More Information
15:17 EDTGECapital One, Apollo Global weigh final bids for GE unit, Bloomberg says
Subscribe for More Information
<< 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use